Use of the cathelicidin LL-37 and derivatives thereof for wound healing

US8506994B2 · kind B2 · utility

Assignee

• Lipopeptide AB · SE

Inventors

• Mona Ståhle-Bäckdahl · Stockholm, SE
• Johan Heilborn · Stockholm, SE
• Anders Carlsson · Lund, SE
• Conny Bogentoft · Nordstraße, SE

Key dates

• Filing date: Jul 28, 2011
• Grant date: Aug 13, 2013
• Expiry date: Jul 28, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2500/36
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.